We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Financials 0.03%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBNX
101
Beta Bionics
BBNX
$803M
$723K 0.02%
72,152
-133
-0.2% -$1.97K
BIIB icon
102
Biogen
BIIB
$31B
$670K 0.02%
3,653
+88
+2% +$16.2K
LEGN icon
103
Legend Biotech
LEGN
$3.91B
$649K 0.02%
35,886
-28,085
-44% -$535K
CSCO icon
104
Cisco
CSCO
$440B
$621K 0.01%
8,000
– –
NBIX icon
105
Neurocrine Biosciences
NBIX
$15.6B
$612K 0.01%
4,646
-1,698,658
-100% -$225M
BABA icon
106
Alibaba
BABA
$297B
$590K 0.01%
4,700
– –
CYTK icon
107
Cytokinetics
CYTK
$10.3B
$583K 0.01%
8,841
-384
-4% -$24.4K
CERT icon
108
Certara
CERT
$1.22B
$567K 0.01%
99,442
– –
PRAX icon
109
Praxis Precision Medicines
PRAX
$10.2B
$566K 0.01%
+1,757
New +$544K
PG icon
110
Procter & Gamble
PG
$335B
$563K 0.01%
3,900
– –
MA icon
111
Mastercard
MA
$499B
$550K 0.01%
1,100
– –
COR icon
112
Cencora
COR
$59.4B
$539K 0.01%
1,716
+1,195
+229% +$417K
AXSM icon
113
Axsome Therapeutics
AXSM
$11.3B
$538K 0.01%
3,181
-24,419
-88% -$4.22M
GDX icon
114
VanEck Gold Miners ETF
GDX
$27.4B
$528K 0.01%
5,750
-9,750
-63% -$961K
AGMB
115
AgomAb Therapeutics NV
AGMB
$663M
$525K 0.01%
+50,000
New +$708K
BLK icon
116
Blackrock
BLK
$182B
$433K 0.01%
450
– –
V icon
117
Visa
V
$682B
$423K 0.01%
1,400
– –
CNTA
118
DELISTED
Centessa Pharmaceuticals
CNTA
$359K 0.01%
+9,030
New +$231K
DNLI icon
119
Denali Therapeutics
DNLI
$3.9B
$341K 0.01%
17,766
+10,628
+149% +$211K
GPCR icon
120
Structure Therapeutics
GPCR
$3.8B
$328K 0.01%
6,803
-138,364
-95% -$9.47M
JD icon
121
JD.com
JD
$39.1B
$325K 0.01%
11,000
– –
ALKS icon
122
Alkermes
ALKS
$8.26B
$314K 0.01%
8,870
+2,276
+35% +$70.6K
GRMN
123
Garmin
GRMN
$60B
$306K 0.01%
1,321
-405
-23% -$90.7K
SMMT icon
124
Summit Therapeutics
SMMT
$10.8B
$301K 0.01%
15,858
+1,596
+11% +$25.8K
ACN icon
125
Accenture
ACN
$108B
$297K 0.01%
1,500
– –
3 4
5
6 7

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
BMO
Beck Mack & Oliver New York $4.85B AUM 9.66% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.